Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder that usually follows an indolent clinical course. However, some patients show an aggressive clinical course leading to death. We explored the risk factors predicting poor prognosis in WM patients. Methods: We retrospectively analyzed 47 patients diagnosed with WM between 2000 and 2018 to explore risk factors predicting poor prognosis using various clinical and laboratory parameters and risk models including the International Prognostic Staging System for WM (IPSS-WM). Results: Over a median follow-up duration of 80.4 months, 29 patients died. The main causes of death were disease progression, organ failure related to amyloidosis, and infection. The median overall survival (OS) was 55.1 months, and 14 patients, including three with amyloidosis, died within 2 years. Serum β2- microglobulin level higher than 4 mg/dL was significantly associated with poor OS. Accordingly, the IPSS-WM showed a significant association with poor prognosis compared with other risk models, and the low-risk group had better OS than intermediate- and high-risk groups. In the retrospective analysis using the results of targeted sequencing in two cases representing good and bad prognosis, different patterns of mutation profiles were observed, including mutations of MYD88, TP53, ARID1A, and JAK2 in a refractory case. Conclusions: Serum β2-microglobulin could be a single biomarker strongly predictive of poor survival of WM patients, and the low-risk group of the IPSS-WM risk model including serum β2-microglobulin has better prognostic value than other risk models. Mutation analysis also might provide additional information to predict high-risk patients.
Abstract
Background/Aims: Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder that usually follows an indolent clinical course. However, some patients show an aggressive clinical course leading to death. We explored the risk factors predicting poor prognosis in WM patients. Methods: We retrospectively analyzed 47 patients diagnosed with WM between 2000 and 2018 to explore risk factors predicting poor prognosis using various clinical and laboratory parameters and risk models including the International Prognostic Staging System for WM (IPSS-WM). Results: Over a median follow-up duration of 80.4 months, 29 patients died. The main causes of death were disease progression, organ failure related to amyloidosis, and infection. The median overall survival (OS) was 55.1 months, and 14 patients, including three with amyloidosis, died within 2 years. Serum β2- microglobulin level higher than 4 mg/dL was significantly associated with poor OS. Accordingly, the IPSS-WM showed a significant association with poor prognosis compared with other risk models, and the low-risk group had better OS than intermediate- and high-risk groups. In the retrospective analysis using the results of targeted sequencing in two cases representing good and bad prognosis, different patterns of mutation profiles were observed, including mutations of MYD88, TP53, ARID1A, and JAK2 in a refractory case. Conclusions: Serum β2-microglobulin could be a single biomarker strongly predictive of poor survival of WM patients, and the low-risk group of the IPSS-WM risk model including serum β2-microglobulin has better prognostic value than other risk models. Mutation analysis also might provide additional information to predict high-risk patients.
참고문헌 (30)
- Brandefors L, "Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies : a population-based study from northern Sweden", Acta Oncol, 55, pp.91~98 (2016)
- Owen RG, "Developing diagnostic criteria in Waldenstrom’s macroglobulinemia", Semin Oncol, 30, pp.196~200 (2003)
- Bufalino SB, "Disease characteristics, treatment patterns, and patient outcomes of lymphoplasmacytic lymphoma or Waldenstroms macroglobulinemia : a single institution retrospective review", Blood, 128, pp.5341~ (2016)
- Kyle RA, "Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia", Semin Oncol, 30, pp.116~120 (2003)
- Zheng YH, "Rituximab-based combination therapy in patients with Waldenstrom macroglobulinemia : a systematic review and meta-analysis", Onco Targets Ther, 12, pp.2751~2766 (2019)
- Dimopoulos MA, "Phase 3trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia", N Engl J Med, 378, pp.2399~2410 (2018)
- Brandefors L, "Prognostic factors and primary treatment for Walden ström macroglobulinemia : a Swedish Lymphoma Registry study", Br J Haematol, 183, pp.564~577 (2018)
- Morel P, "International prognostic scoring system for Waldenstrom macroglobulinemia", Blood, 113, pp.4163~4170 (2009)
- Dhodapkar MV, "Long-term survival in Waldenstrom macroglobulinemia : 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003", Blood, 113, pp.793~796 (2009)
- Ghobrial IM, "Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia", Br J Haematol, 133, pp.158~164 (2006)
- Morel P, "Patients with the description of a new scoring system and its validation on 253 other patients", Blood, 96, pp.852~858 (2000)
- Bustoros M, "Progression risk stratification of asymptomatic Waldenström macroglobulinemia", J Clin Oncol, 37, pp.1403~1411 (2019)
- Treon SP, "Update on treatment recommendations from the Third International Workshop on Waldenstrom’s macroglobulinemia", Blood, 107, pp.3442~3446 (2006)
- Hyeon J, "Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement", Mod Pathol, 31, pp.1418~1428 (2018)
- Shin HT, "Prevalence and detection of low-allele-fraction variants in clinical cancer samples", Nat Commun, 8, pp.1377~ (2017)
- Wilm A, "LoFreq : a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets", Nucleic Acids Res, 40, pp.11189~11201 (2012)
- Cibulskis K, "Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples", Nat Biotechnol, 31, pp.213~219 (2013)
- Buske C, "The addition of rituximab to front-line therapy with CHOP(R-CHOP)results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma : results of a randomized trial of the German Low-Grade Lymphoma Study Group(GLSG)", Leukemia, 23, pp.153~161 (2009)
- Rummel MJ, "Bendamustine plus rituximab versus CHOP plus rituximab as firstline treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial", Lancet, 381, pp.1203~1210 (2013)
- 신상용, "Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma", Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas, 2016, pp.51(3), 181~186[DOI]
- 김진만, "WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study", Journal of Pathology and Translational Medicine, 45(3), pp.254~260 (2011), 대한병리학회
- Dimopoulos MA, "Treatment recommendations for patients with Waldenström macroglobulinemia(WM)and related disorders : IWWM-7consensus", Blood, 124, pp.1404~1411 (2014)
- Treon SP, "How I treat Waldenström macroglobulinemia", Blood, 126, pp.721~732 (2015)
- Milani P, "Monoclonal IgM-related AL amyloidosis", Best Pract Res Clin Haematol, 29, pp.241~248 (2016)
- Kyle RA, "Primary systemic amyloidosis : clinical and laboratory features in 474 cases", Semin Hematol, 32, pp.45~59 (1995)
- Treon SP, "MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia", N Engl J Med, 367, pp.826~833 (2012)
- Treon SP, "MYD88 wild-type Waldenstrom macroglobulinaemia : differential diagnosis, risk of histological transformation, and overall survival", Br J Haematol, 180, pp.374~380 (2018)
- Abeykoon JP, "MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia", Am J Hematol, 93, pp.187~194 (2018)
- Poulain S, "TP53 mutation and its prognostic significance in Waldenstrom’s macroglobulinemia", Clin Cancer Res, 23, pp.6325~6335 (2017)
- Hunter ZR, "Genomics, signaling, and treatment of Waldenström macroglobulinemia", J Clin Oncol, 35, pp.994~1001 (2017)